GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hainan Poly Pharm Co Ltd (SZSE:300630) » Definitions » Total Long-Term Liabilities

Hainan Poly Pharm Co (SZSE:300630) Total Long-Term Liabilities : ¥2,134 Mil (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Hainan Poly Pharm Co Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Hainan Poly Pharm Co's Total Long-Term Liabilities for the quarter that ended in Sep. 2023 was ¥2,134 Mil.

Hainan Poly Pharm Co Total Long-Term Liabilities Historical Data

The historical data trend for Hainan Poly Pharm Co's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hainan Poly Pharm Co Total Long-Term Liabilities Chart

Hainan Poly Pharm Co Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 61.90 141.52 342.29 1,080.80 1,672.41

Hainan Poly Pharm Co Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,579.15 1,672.41 2,010.23 2,348.11 2,133.83

Hainan Poly Pharm Co Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Hainan Poly Pharm Co Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Hainan Poly Pharm Co's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Hainan Poly Pharm Co (SZSE:300630) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hainan Poly Pharm Co Ltd (SZSE:300630) » Definitions » Total Long-Term Liabilities
Comparable Companies
SHSE:603567 SZSE:002038 SZSE:002424 SHSE:600267 SZSE:002099 SHSE:600211 SZSE:000766 SZSE:002332 SHSE:600750 SZSE:002020 ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
N/A
Address
No.1509 Binsheng Road, 10th Floor, Zhejiang Province, Hangzhou, CHN, 310051
Website
http://www.hnpoly.com
Hainan Poly Pharm Co Ltd is a pharmaceutical manufacturer in China. It manufactures injections, oral solid formulations, dry suspension, and other active pharmaceutical ingredients. The products offered by the company include Azithromycin for Injection, Ganciclovir Sodium for Injection. Octreotide Acetate Injection, Trimebutine Maleate tablets, Desloratadine, Trimebutine Maleate, and GANCICLOVIR among others.
Executives
Fan De Zhu Independent director
Xie Hui Fang Supervisors
Pu Jian Executives
Xu Zhao Securities Affairs Representative
Shen Shi Hua Executives
Zhou Mao Directors, Directors, and Executives

Hainan Poly Pharm Co (SZSE:300630) Headlines

No Headlines